CELC Celcuity Inc.

Price Chart

Executive Summary

Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increased from $400M, with an underwriter option for an additional $75M. Net proceeds of ~$484.3M (or ~$557M with over-allotment) will repay Oxford Finance debt and fund working capital, including clinical trials and potential commercialization. The conversion premium of ~40% above the last sale price signals moderate dilution risk, but the large capital raise provides a multi-year cash runway for a pre-revenue biotech awaiting FDA action on gedatolisib.

Key Financial Metrics

Actionable Insight

Key Facts

• Upsized convertible notes offering: $500M aggregate principal, increased from $400M.
• 0.250% coupon, maturing August 1, 2032; semi-annual interest payments.
• Initial conversion price ~$124.53 per share, ~40% premium above last reported sale price on June 3, 2026.
• Underwriters have 30-day option to purchase up to an additional $75M in notes for over-allotments.
• Net proceeds estimated at ~$484.3M (or ~$557M if over-allotment exercised in full).
• Proceeds to repay all outstanding obligations under Oxford Finance loan agreement; remainder for working capital, clinical trials, and potential commercialization.
• Offering expected to close June 8, 2026, subject to customary conditions.
• Company is clinical-stage, pre-revenue, with lead candidate gedatolisib in Phase 3 for HR+/HER2- breast cancer.
• Conversion premium of 40% provides some cushion against near-term dilution, but full conversion at $124.53 would add significant share count.
• Historical performance on CELC reports shows negative average returns at T+20 (-2.23%) and low win rate (33%), suggesting caution.

Financial Impact

Net proceeds of ~$484.3M (or ~$557M with over-allotment) provide substantial capital for a pre-revenue biotech with ~$4.3B market cap. Full conversion at $124.53 would add ~4.0M shares (based on $500M / $124.53), representing roughly 5-6% dilution relative to current shares outstanding (estimated from market cap and stock price). The 0.250% coupon is minimal interest expense.

Risk Factors

• Dilution risk: Full conversion of notes at $124.53 would add ~4M shares, potentially pressuring stock price.
• Execution risk: Proceeds used for clinical trials and commercialization; failure of gedatolisib to gain FDA approval would leave company with high cash burn and no revenue.
• Market risk: Convertible notes may create overhang if stock trades near conversion price, encouraging arbitrage activity.
• Historical calibration: Past CELC reports show negative average T+20 returns (-2.23%) and low win rate (33%), suggesting the market may react negatively to this capital raise despite the cash infusion.

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status